Books in Drug manufacturing and packaging

11-17 of 17 results in All results

Predictive Modeling of Pharmaceutical Unit Operations

• 1st Edition
• April 9, 2014
• Preetanshu Pandey + 1 more
• English
• Hardback 978-0-08-100154-7

  9 7 8 - 0 - 0 8 - 1 0 0 1 5 4 - 7
• eBook 978-0-08-100180-6

  9 7 8 - 0 - 0 8 - 1 0 0 1 8 0 - 6

The use of modeling and simulation tools is rapidly gaining prominence in the pharmaceutical industry covering a wide range of applications. This book focuses on modeling and simulation tools as they pertain to drug product manufacturing processes, although similar principles and tools may apply to many other areas. Modeling tools can improve fundamental process understanding and provide valuable insights into the manufacturing processes, which can result in significant process improvements and cost savings. With FDA mandating the use of Qualityby Design (QbD) principles during manufacturing, reliable modeling techniques can help to alleviate the costs associated with such efforts, and be used to create in silico formulation and process design space. This book is geared toward detailing modeling techniques that are utilized for the various unit operations during drug product manufacturing. By way of examples that include case studies, various modeling principles are explained for the nonexpert end users. A discussion on the role of modeling in quality risk management for manufacturing and application of modeling for continuous manufacturing and biologics is also included.

Orphan Drugs

• 1st Edition
• October 31, 2013
• Elizabeth Hernberg-Ståhl + 1 more
• English
• Hardback 978-1-907568-09-1

  9 7 8 - 1 - 9 0 7 5 6 8 - 0 9 - 1
• eBook 978-1-908818-39-3

  9 7 8 - 1 - 9 0 8 8 1 8 - 3 9 - 3

This authoritative and comprehensive book makes the reader familiar with the processes of bringing orphan drugs to the global market. There are between 5,000 and 7,000 rare diseases and the number of patients suffering from them is estimated to be more than 50 million in the US and Europe. Before the orphan drug legislation enacted in the US in 1983, there was a limited interest from industry to develop treatment for very small patient groups. One of the difficulties is, of course, that similar levels of investment are needed from a pharmaceutical company to bring a drug to the market for both small and large patient groups.The journey from application of an orphan drug designation to a reimbursed market- approved drug is long and many obstacles occur during the journey.After reading the book, readers will: Understand who the players/stakeholders are in the rare orphan disease field and their specific needs and concerns: patients and patient organizations, researchers and treating physicians within the field, industry, regulatory and reimbursement bodies* Understand the strong partnership between the different players and the various initiatives to improve and increase access to treatment for patients; minimizing the gap between numbers of known diseases, orphan designations, approved drugs and paid drugs.The book also provides short practical case stories from patients and researchers, as well as representatives from industry and authorities on the challenges they came across in developing orphan drugs or getting access to orphan drugs.

Formulation Tools for Pharmaceutical Development

• 1st Edition
• September 30, 2013
• J E Aguilar
• English
• Hardback 978-1-907568-99-2

  9 7 8 - 1 - 9 0 7 5 6 8 - 9 9 - 2
• eBook 978-1-908818-50-8

  9 7 8 - 1 - 9 0 8 8 1 8 - 5 0 - 8

A range of new and innovative tools used for preformulation and formulation of medicines help optimize pharmaceutical development projects. Such tools also assist with the performance evaluation of the pharmaceutical process, allowing any potential gaps to be identified. These tools can be applied in both basic research and industrial environment. Formulation tools for pharmaceutical development considers these key research and industrial tools.Nine chapters by leading contributors cover: Artificial neural networks technology to model, understand, and optimize drug formulations; ME_expert 2.0: a heuristic decision support system for microemulsions formulation development; Expert system for the development and formulation of push-pull osmotic pump tablets containing poorly water-soluble drugs; SeDeM Diagram: an expert system for preformulation, characterization and optimization of tables obtained by direct compression; New SeDeM-ODT expert system: an expert system for formulation of orodispersible tablets obtained by direct compression; and 3D-cellular automata in computer-aided design of pharmaceutical formulations: mathematical concept and F-CAD software.

The Path from Biomarker Discovery to Regulatory Qualification

• 1st Edition
• July 16, 2013
• Federico Goodsaid + 1 more
• English
• Paperback 978-0-12-391496-5

  9 7 8 - 0 - 1 2 - 3 9 1 4 9 6 - 5
• eBook 978-0-12-394408-5

  9 7 8 - 0 - 1 2 - 3 9 4 4 0 8 - 5

The Path from Biomarker Discovery to Regulatory Qualification is a unique guide that focuses on biomarker qualification, its history and current regulatory settings in both the US and abroad. This multi-contributed book provides a detailed look at the next step to developing biomarkers for clinical use and covers overall concepts, challenges, strategies and solutions based on the experiences of regulatory authorities and scientists. Members of the regulatory, pharmaceutical and biomarker development communities will benefit the most from using this book—it is a complete and practical guide to biomarker qualification, providing valuable insight to an ever-evolving and important area of regulatory science. For complimentary access to chapter 13, 'Classic' Biomarkers of Liver Injury, by John R. Senior, Associate Director for Science, Food and Drug Administration, Silver Spring, Maryland, USA, please visit the following site: http://tinyurl.com/ClassicBiomarkers

Inhaler Devices

• 1st Edition
• April 23, 2013
• Polina Prokopovich
• English
• eBook 978-0-85709-869-6

  9 7 8 - 0 - 8 5 7 0 9 - 8 6 9 - 6

Given their direct impact on the health and quality of life for millions, inhalers represent a major turning point in the history of modern medicine. Inhaler devices: Fundamentals, design and drug delivery provides readers with an introduction to the fundamentals of inhaler technology, with a comprehensive discussion of the history of inhalers as well as a discussion on current research and development.Part one discusses the fundamentals and development of inhaler devices as well as drug formulations for inhalers. The treatment of asthma is also discussed. Part two reviews recent developments in drug formulation and nanotechnology for inhaler devices, emerging inhaler technology and possible future trends.Inhaler devices: Fundamentals, design and drug delivery is an essential design guide for good industrial practice, and will be an invaluable resource for those researching and treating conditions such as asthma; and those developing and manufacturing inhalation devices.

Contract Research and Manufacturing Services (CRAMS) in India

• 1st Edition
• October 31, 2012
• Milind Antani + 1 more
• English
• eBook 978-1-908818-16-4

  9 7 8 - 1 - 9 0 8 8 1 8 - 1 6 - 4

The field of contract research and manufacturing broadly encompasses those services in the pharmaceutical and biotechnology sectors that require extensive research and development and large-scale manufacturing facilities. The field has great potential for growth in the Indian outsourcing industry, which is world-renowned for its provision of cheap and highly-skilled services. Contract research and manufacturing services (CRAMS) in India provides a detailed account of the current scenario in India and the advantages that the Indian outsourcing industry can offer in the field of CRAMS. Following an overview of the services and their emergence in India, chapters in the book begin by discussing the legal and regulatory scenario and major concerns and issues. In the latter part of the book, topics covered include service agreements, dispute resolution and contract negotiations, followed by a discussion of the outlook for CRAMS in India and some concluding remarks. Several appendices are included, offering a list of major players in the field and various forms for use in licence applications.

Therapeutic Protein Drug Products

• 1st Edition
• January 2, 2012
• Brian K Meyer
• English
• Hardback 978-1-907568-18-3

  9 7 8 - 1 - 9 0 7 5 6 8 - 1 8 - 3
• eBook 978-1-908818-10-2

  9 7 8 - 1 - 9 0 8 8 1 8 - 1 0 - 2

Therapeutic protein drug products provides a comprehensive overview of therapeutic protein drug products, with an emphasis on formulation beginning in the laboratory, followed by manufacturing and administration in the clinic. A list of many commercial therapeutic drug products are described and include the product name, dosages, active concentration, buffer, excipients, Ph, container type and route of administration. The laboratory formulation sections focus on the most common buffers, excipients, and Ph ranges that are commonly tested in addition to systematic approaches. A brief section on biophysical and analytical analysis is also provided. Properties of therapeutic protein formulations are described and include opalescence, phase separation, color, and subvisible particles. An emphasis is placed on material and process testing to ensure success during manufacturing. The drug product manufacturing process, which includes the process of compounding to filling, is also covered. Methods of delivery in the clinic are addressed, as well as delivery strategies. Finally, a perspective on the regulatory requirements for therapeutic protein formulations is discussed.